comparemela.com


Endeavor BioMedicines raises $62 million to combat pulmonary disease
A new startup has officially emerged from stealth with the raise of its $62 million Series A funding round. Endeavor BioMedicines is led by co-founder and CEO John Hood, who previously led Impact Biomedicines, and its new funding comes from Omega Funds and Longitude Capital, as well as the company’s own management team. Endeavor is also co-founded by Miguel de los Rios, who serves as its chief science officer and who was previously CEO of Rift Biotherapeutics.
Endeavor’s goal is to develop treatments specifically to address pulmonary disease, and the startup is putting its funding toward two phase 2 clinical trials that will seek to determine whether their therapeutic candidate can reverse or slow the progression of idiopathic pulmonary fibrosis (IPF), a very common type of pulmonary fibrosis that results in long tissue scarring that causes difficulty in breathing for affected patients.

Related Keywords

John Hood ,Los Rios ,Celgene Corp ,Impact Biomedicines ,Omega Funds ,Longitude Capital ,Miguel De Los Rios ,Chief Science Officer ,ஜான் ஹூட் ,லாஸ் ரியோஸ் ,செல்ஜீன் கார்ப் ,ஒமேகா நிதி ,தீர்க்கரேகை மூலதனம் ,மிகுவல் டி லாஸ் ரியோஸ் ,தலைமை அறிவியல் அதிகாரி ,

© 2024 Vimarsana

comparemela.com © 2020. All Rights Reserved.